Articles published by Evaxion Biotech







Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations
February 29, 2024
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX

Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
February 20, 2024
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX

Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement
February 07, 2024
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX

Evaxion Announces Closing of $15 Million Public Offering
February 06, 2024
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX

Evaxion Biotech Announces Pricing of $15 Million Public Offering
February 01, 2024
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX

Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets
January 24, 2024
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX

Evaxion Announces Completion of ADS Ratio Change
January 22, 2024
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX

Evaxion Announces Plan to Implement ADS Ratio Change
January 08, 2024
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX

Evaxion Biotech Announces Closing of Private Placement
December 21, 2023
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX


Evaxion Biotech Announces Private Placement Financing
December 19, 2023
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX

Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept
November 28, 2023
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX

Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer Immunotherapy
November 15, 2023
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX

Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak
November 06, 2023
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX

Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01
October 31, 2023
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX

New and Exciting Clinical Data on Evaxion’s AI-Immunology™-Based Personalized Cancer Vaccines to be Presented
October 26, 2023
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX


Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea
September 20, 2023
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX

Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company
September 18, 2023
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX




Evaxion announces financing commitments totaling up to USD 20 million with Negma Group
August 01, 2023
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free